Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management (The TRIUMPH Study)
Open Access
- 30 December 2024
- journal article
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 7 (1) , otaf013
Abstract
Background: Tofacitinib is a rapidly acting Janus kinase (JAK) inhibitor with increasing evidence of effectiveness in patients with acute severe ulcerative colitis (ASUC). However, there are scarce prospective data analyzing the efficacy and rapidity of action in hospitalized ASUC. Methods: The TRIUMPH study is a prospective open-label interventional trial of tofacitinib in hospitalized patients with ASUC conducted in 5 hospitals across Canada (Clinicaltrials.gov: NCT04925973). Eligible participants included biologic-naïve and experienced patients with ASUC refractory to 3 days of intravenous (IV) corticosteroids (Modified Truelove-Witts Severity Index [MTWSI] > 10 despite steroids). Participants were treated with tofacitinib 10 mg twice daily and assessed daily while in hospital. The primary outcome was day 7 clinical response (MTWSI reduction of > 3 from baseline and ≤ 10). Results: Among 24 subjects, 33.3% (8/24) had previous anti-TNF failure. Day 7 clinical response was achieved in 58.3% (14/24). The mean number of days to achieve clinical response was 2.4 (SD 1.3). Marked reduction in C-reactive protein was observed in responders within the first two days after tofacitinib initiation compared to nonresponders. Colectomy occurred in 25% (6/24) by 6 months, with no additional colectomy beyond this time point. Five participants reported a total of 13 adverse events. Conclusions: Tofacitinib is an effective rescue therapy in hospitalized patients with steroid-refractory ASUC. Randomized controlled trials are warranted to compare JAK inhibitors with other rescue therapies, including infliximab in steroid-refractory ASUC (Clinicaltrials.gov: NCT04925973).Keywords
Funding Information
- Pfizer Canada Inc
This publication has 22 references indexed in Scilit:
- Acute severe ulcerative colitis: from pathophysiology to clinical managementNature Reviews Gastroenterology & Hepatology, 2016
- Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trialThe Lancet Gastroenterology & Hepatology, 2016
- Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative ColitisClinical Gastroenterology and Hepatology, 2016
- Statistical comparison of the slopes of two regression lines: A tutorialAnalytica Chimica Acta, 2014
- The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Tofacitinib, a Janus Kinase Inhibitor, in HumansDrug Metabolism and Disposition, 2014
- Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trialThe Lancet, 2012
- Treatment of Hospitalized Adult Patients With Severe Ulcerative Colitis: Toronto Consensus StatementsAmerican Journal of Gastroenterology, 2012
- The pattern and outcome of acute severe colitisJournal of Crohn's and Colitis, 2010
- Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitisInt. Journal of Clinical Pharmacology and Therapeutics, 2010
- Response to Corticosteroids in Severe Ulcerative Colitis: A Systematic Review of the Literature and a Meta-RegressionClinical Gastroenterology and Hepatology, 2007